Diseases [C] » Neoplasms [C04] » Neoplasms by Histologic Type » Leukemia » Leukemia, Lymphoid » Leukemia, B-Cell
Diseases [C] » Hemic and Lymphatic Diseases [C15] » Lymphatic Diseases » Lymphoproliferative Disorders » Leukemia, Lymphoid » Leukemia, B-Cell
Diseases [C] » Immune System Diseases [C20] » Immunoproliferative Disorders » Lymphoproliferative Disorders » Leukemia, Lymphoid » Leukemia, B-Cell
Description
A malignant disease of the B-LYMPHOCYTES in the bone marrow and/or blood. MeSH
Hierarchy View
Subtype Terms (2)
Leukemia, Lymphocytic, Chronic, B-Cell
602 drugs (221 approved, 381 experimental)
Leukemia, Prolymphocytic, B-Cell
22 drugs (15 approved, 7 experimental)
Phase 4 Indicated Drugs (1)
Phase 3 Indicated Drugs (2)
Phase 2 Indicated Drugs (29)
Phase 1 Indicated Drugs (46)
Other Experimental Indicated Drugs (3)
Organization Involved with Phase 4 Indications (1)
Organization Involved with Phase 3 Indications (4)
Organization Involved with Phase 2 Indications (25)
Organization Involved with Phase 1 Indications (32)
Organization Involved with Other Experimental Indications (4)
Hierarchy Tree View
UMLS Data
YOU AGREE THAT THE INFORMATION PROVIDED ON THIS WEBSITE IS PROVIDED “AS IS”, WITHOUT ANY WARRANTY OF ANY KIND, EXPRESSED OR IMPLIED, INCLUDING WITHOUT LIMITATION WARRANTIES OF MERCHANTABILITY OR FITNESS FOR ANY PARTICULAR PURPOSE, OR NON-INFRINGEMENT OF ANY THIRD-PARTY PATENT, COPYRIGHT, OR ANY OTHER THIRD-PARTY RIGHT. IN NO EVENT SHALL THE CREATORS OF THE WEBSITE OR WASHINGTON UNIVERSITY BE LIABLE FOR ANY DIRECT, INDIRECT, SPECIAL, OR CONSEQUENTIAL DAMAGES ARISING OUT OF OR IN ANY WAY CONNECTED WITH THE WEBSITE, THE USE OF THE WEBSITE, OR THIS AGREEMENT, WHETHER IN BREACH OF CONTRACT, TORT OR OTHERWISE, EVEN IF SUCH PARTY IS ADVISED OF THE POSSIBILITY OF SUCH DAMAGES.
